All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
Phase 1/1b Study To Evaluate The Safety And Activity Of TTX-030 (Anti-CD39) In Combination With Budigalimab And/Or Chemotherapy In Subjects With Advanced Solid Tumors
To test the safety of TTX-030 combination therapy in various cancer types
To see if TTX-030 combination therapy works against various cancer types
To see how much TTX-030 combination therapy is in the blood at specific times after dosing and how the body eliminates TTX-030
To see what effects TTX-030 combination therapy has on the body
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer
A Phase I, Open-Label, Multicenter, Study of WVT078 in Subjects with Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 FIH Study of REGN5459 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients with Relapsed or Refractory Multiple Myeloma
A Phase 1b Trial of Magrolimab Monotherapy Or Magrolimab In Combination With Azacitidine In Patients With Hematological Malignancies
A Phase I/Ib Open-label, Multi-center Dose Escalation Study of JBH492 in Patients with Relapsed/refractory Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for the Treatment of Subjects with Multiple Myeloma
1. Combination 1: JNJ-64407564 [anti-GPRC5DxCD3] and Dara SC
2. Combination 2: JNJ-64007957 [anti-BCMAxCD3] and Dara SC
Another purpose of this study is to find out how long JNJ-64407564 [anti-GPRC5DxCD3] or JNJ-64007957 [anti-BCMAxCD3] in combination with Dara SC stay in and act on your body. This is measured by blood tests.
A Phase 1, Open-Label, Study Of Voruciclib In Subjects With Relapsed And/Or Refractory B Cell Malignancies Or Acute Myeloid Leukemia After Failure Of Prior Standard Therapies
A Phase 1/2 Trial of MRTX849 in Combination with TNO155 in Patients with Advanced Solid Tumors with KRAS G12C Mutation
gene mutation (KRAS G12C mutation) that is thought to cause cancer cells to grow. MRTX849
is designed to block this mutant protein and thereby prevent the growth and spread of the cancer.
The purposes of this study are to determine the right dose of GNX102 that can be tolerated by people with cancer, and, if it can shrink the tumors.
A Phase 1/1b, First-In-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Oral TP-1454 Alone And In Combination With Ipilimumab And Nivolumab
A Multicenter, Phase 1, Open-Label, Dose-Escalation and Expansion Study Of TNB-486, A Bispecific Antibody, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
The purpose of the Study is:
• To find the highest dose of the study drug that can be given without causing severe side effects.
• To identify side effects of the study drug at different doses.
• To gather early information about how well the study drug treats lymphoma
• To measure the amount of the study drug in the blood at different timepoints after study drug administration, at different doses.
• To evaluate biomarkers in your blood or other parts of your body. A biomarker is a substance in your blood or other location that may tell us something about your disease, indicate how your disease is progressing, or provide information about how effective a study drug is.
A Phase I/II Study of TheraT® Vector(s) Expressing Human Papillomavirus 16 Positive (HPV 16+) Specific Antigens in Patients with HPV 16+ Confirmed Cancers
A Phase 1/2, Dose Escalation Safety And Tolerability Study Of AO-176 As Monotherapy And In Combination With Bortezomib And Dexamethasone In Adults With Relapsed Or Refractory Multiple Myeloma
An Open-label, Phase II, Platform Trial Evaluating Safety and Efficacy of Multiple BI 754091 Anti-PD-1 Based Combination Regimens in PD-(L)1 Naïve and PD-(L)1 Pretreated Patient Populations with Advanced and/or Metastatic Solid Tumours Who Have Had at Least One Line of Systemic Therapy
penis, esophagus, and vulva; hepatocellular carcinoma; biliary tract carcinoma, small-cell lung cancer;
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects with Nonsmall Cell Lung Cancer (NSCLC)
The vaccine, BI 1361849, also works by stimulating the body’s immune system to fight and destroy cancer cells. There are six different ingredients in the vaccine that each produce a different antibody response to tumor cells. The vaccine is given through an injection into your skin.
A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
What are the side effects of MGD006?
What is the highest dose of MGD006 that can be given safely?
How long does MGD006 stay in the blood?
How long does it take for MGD006 to leave the body?
Is MGD006 a possible treatment for AML?